Tübingen-based biotech company, Acousia Therapeutics GmbH, has announced the randomization of the first patient for their PROHEAR-Study on February 15, 2024. The study, which is a placebo-controlled, Phase 2a trial with a split-body design, aims to investigate the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens.
No responses yet